Compile Data Set for Download or QSAR
maximum 50k data
Found 35 Enz. Inhib. hit(s) with all data for entry = 91
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM50027366(Ketazocine | US10081602, Example Ketazocine | US10...)
Affinity DataKi:  1.30nM ΔG°:  -50.7kJ/mole IC50:  5.60nMpH: 7.5 T: 2°CAssay Description:Competition binding experiments were conducted by incubating membrane protein to equilibrium in triplicate in the presence of a fixed concentration o...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168148(US10081602, Example 20 | US10865186, Compound 20 |...)
Affinity DataKi:  2.86nM ΔG°:  -48.8kJ/molepH: 7.5 T: 2°CAssay Description:Competition binding experiments were conducted by incubating membrane protein to equilibrium in triplicate in the presence of a fixed concentration o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168147(US10081602, Example 12 | US9688638, 12)
Affinity DataKi:  5nM ΔG°:  -47.4kJ/molepH: 7.5 T: 2°CAssay Description:Competition binding experiments were conducted by incubating membrane protein to equilibrium in triplicate in the presence of a fixed concentration o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168148(US10081602, Example 20 | US10865186, Compound 20 |...)
Affinity DataKi:  44nM ΔG°:  -42.0kJ/molepH: 7.5 T: 2°CAssay Description:Competition binding experiments were conducted by incubating membrane protein to equilibrium in triplicate in the presence of a fixed concentration o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168147(US10081602, Example 12 | US9688638, 12)
Affinity DataKi:  58nM ΔG°:  -41.3kJ/molepH: 7.5 T: 2°CAssay Description:Competition binding experiments were conducted by incubating membrane protein to equilibrium in triplicate in the presence of a fixed concentration o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168144(US10865186, Compound 4 | US9688638, 4 | US9688638,...)
Affinity DataKi:  203nM ΔG°:  -38.2kJ/mole IC50:  879nMpH: 7.5 T: 2°CAssay Description:Competition binding experiments were conducted by incubating membrane protein to equilibrium in triplicate in the presence of a fixed concentration o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168150(US10081602, Example 24 | US10865186, Compound 24 |...)
Affinity DataKi:  494nM ΔG°:  -36.0kJ/molepH: 7.5 T: 2°CAssay Description:Competition binding experiments were conducted by incubating membrane protein to equilibrium in triplicate in the presence of a fixed concentration o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM166783(US9688638, 1 | US9688638, 2 | US9688638, 3)
Affinity DataKi:  549nM ΔG°:  -35.7kJ/mole IC50:  2.38E+3nMpH: 7.5 T: 2°CAssay Description:Competition binding experiments were conducted by incubating membrane protein to equilibrium in triplicate in the presence of a fixed concentration o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM166783(US9688638, 1 | US9688638, 2 | US9688638, 3)
Affinity DataKi:  619nM ΔG°:  -35.4kJ/mole IC50:  2.68E+3nMpH: 7.5 T: 2°CAssay Description:Competition binding experiments were conducted by incubating membrane protein to equilibrium in triplicate in the presence of a fixed concentration o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM166783(US9688638, 1 | US9688638, 2 | US9688638, 3)
Affinity DataKi:  769nM ΔG°:  -34.9kJ/mole IC50:  3.33E+3nMpH: 7.5 T: 2°CAssay Description:Competition binding experiments were conducted by incubating membrane protein to equilibrium in triplicate in the presence of a fixed concentration o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168151(US10081602, Example 25 | US9688638, 25)
Affinity DataKi:  955nM ΔG°:  -34.4kJ/molepH: 7.5 T: 2°CAssay Description:Competition binding experiments were conducted by incubating membrane protein to equilibrium in triplicate in the presence of a fixed concentration o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168149(US10081602, Example 23 | US10865186, Compound 23 |...)
Affinity DataKi:  1.06E+3nM ΔG°:  -34.1kJ/molepH: 7.5 T: 2°CAssay Description:Competition binding experiments were conducted by incubating membrane protein to equilibrium in triplicate in the presence of a fixed concentration o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168144(US10865186, Compound 4 | US9688638, 4 | US9688638,...)
Affinity DataKi:  1.40E+3nM ΔG°:  -33.4kJ/mole IC50:  6.08E+3nMpH: 7.5 T: 2°CAssay Description:Competition binding experiments were conducted by incubating membrane protein to equilibrium in triplicate in the presence of a fixed concentration o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168150(US10081602, Example 24 | US10865186, Compound 24 |...)
Affinity DataKi:  1.81E+3nM ΔG°:  -32.8kJ/molepH: 7.5 T: 2°CAssay Description:Competition binding experiments were conducted by incubating membrane protein to equilibrium in triplicate in the presence of a fixed concentration o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168144(US10865186, Compound 4 | US9688638, 4 | US9688638,...)
Affinity DataKi:  2.96E+3nM ΔG°:  -31.6kJ/mole IC50:  1.28E+4nMpH: 7.5 T: 2°CAssay Description:Competition binding experiments were conducted by incubating membrane protein to equilibrium in triplicate in the presence of a fixed concentration o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168151(US10081602, Example 25 | US9688638, 25)
Affinity DataKi:  3.92E+3nM ΔG°:  -30.9kJ/molepH: 7.5 T: 2°CAssay Description:Competition binding experiments were conducted by incubating membrane protein to equilibrium in triplicate in the presence of a fixed concentration o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168149(US10081602, Example 23 | US10865186, Compound 23 |...)
Affinity DataKi:  7.96E+3nM ΔG°:  -29.1kJ/molepH: 7.5 T: 2°CAssay Description:Competition binding experiments were conducted by incubating membrane protein to equilibrium in triplicate in the presence of a fixed concentration o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM50027366(Ketazocine | US10081602, Example Ketazocine | US10...)
Affinity DataIC50:  8.40nMpH: 7.5 T: 2°CAssay Description:Competition binding experiments were conducted by incubating membrane protein to equilibrium in triplicate in the presence of a fixed concentration o...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM166783(US9688638, 1 | US9688638, 2 | US9688638, 3)
Affinity DataEC50:  153nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168151(US10081602, Example 25 | US9688638, 25)
Affinity DataEC50:  1.21E+3nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM166783(US9688638, 1 | US9688638, 2 | US9688638, 3)
Affinity DataEC50:  122nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168144(US10865186, Compound 4 | US9688638, 4 | US9688638,...)
Affinity DataEC50:  9.35nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168144(US10865186, Compound 4 | US9688638, 4 | US9688638,...)
Affinity DataEC50:  350nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168144(US10865186, Compound 4 | US9688638, 4 | US9688638,...)
Affinity DataEC50:  357nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168147(US10081602, Example 12 | US9688638, 12)
Affinity DataEC50:  7nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168148(US10081602, Example 20 | US10865186, Compound 20 |...)
Affinity DataEC50:  6.10nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168149(US10081602, Example 23 | US10865186, Compound 23 |...)
Affinity DataEC50:  395nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168150(US10081602, Example 24 | US10865186, Compound 24 |...)
Affinity DataEC50:  107nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168151(US10081602, Example 25 | US9688638, 25)
Affinity DataEC50:  195nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM50027366(Ketazocine | US10081602, Example Ketazocine | US10...)
Affinity DataEC50:  0.550nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168147(US10081602, Example 12 | US9688638, 12)
Affinity DataEC50:  189nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168148(US10081602, Example 20 | US10865186, Compound 20 |...)
Affinity DataEC50:  128nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168149(US10081602, Example 23 | US10865186, Compound 23 |...)
Affinity DataEC50:  3.29E+3nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168150(US10081602, Example 24 | US10865186, Compound 24 |...)
Affinity DataEC50:  580nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM166783(US9688638, 1 | US9688638, 2 | US9688638, 3)
Affinity DataEC50:  139nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent